Cargando…

Prognostic role of RDW in hematological malignancies: a systematic review and meta-analysis

BACKGROUND: Red blood cell distribution width (RDW), a biomarker for discrimination of anemia, has been recently identified as a prognostic factor in various types of cancer. Here we performed a meta-analysis in order to assess the correlation between RDW and the survival outcomes in patients with h...

Descripción completa

Detalles Bibliográficos
Autores principales: Ai, Lisha, Mu, Shidai, Hu, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914059/
https://www.ncbi.nlm.nih.gov/pubmed/29713244
http://dx.doi.org/10.1186/s12935-018-0558-3
_version_ 1783316642208415744
author Ai, Lisha
Mu, Shidai
Hu, Yu
author_facet Ai, Lisha
Mu, Shidai
Hu, Yu
author_sort Ai, Lisha
collection PubMed
description BACKGROUND: Red blood cell distribution width (RDW), a biomarker for discrimination of anemia, has been recently identified as a prognostic factor in various types of cancer. Here we performed a meta-analysis in order to assess the correlation between RDW and the survival outcomes in patients with hematologic malignances. PATIENTS/METHODS: We systematically searched PubMed, Embase, and ISI Web of Science for relevant studies, to investigate the prognostic significance of RDW in hematological malignancies. Odds ratios or hazards ratios (HRs) with corresponding 95% confidence intervals (CIs) are pooled to estimate the association between RDW and clinicopathological parameters of patients with hematologic malignances. RESULTS: Seven trials with 1031 patients suffering from hematological malignancies were included in the meta-analysis, and the results indicated that increased pretreatment RDW predicted poor overall survival (HR = 2.35, 95% CI 1.70–3.24), poor progress-free survival (HR = 2.44, 95% CI 1.70–3.49) and poor event-free survival (EFS) (HR = 3.15, 95% CI 1.59–6.25). Furthermore, the similar results were observed in subgroup analysis stratified by cancer type, such as multiple myeloma, and diffuse large B cell lymphoma, etc. CONCLUSIONS: As for hematologic malignances, patients with higher RDW are more likely to have poorer prognosis than those with lower RDW.
format Online
Article
Text
id pubmed-5914059
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-59140592018-04-30 Prognostic role of RDW in hematological malignancies: a systematic review and meta-analysis Ai, Lisha Mu, Shidai Hu, Yu Cancer Cell Int Primary Research BACKGROUND: Red blood cell distribution width (RDW), a biomarker for discrimination of anemia, has been recently identified as a prognostic factor in various types of cancer. Here we performed a meta-analysis in order to assess the correlation between RDW and the survival outcomes in patients with hematologic malignances. PATIENTS/METHODS: We systematically searched PubMed, Embase, and ISI Web of Science for relevant studies, to investigate the prognostic significance of RDW in hematological malignancies. Odds ratios or hazards ratios (HRs) with corresponding 95% confidence intervals (CIs) are pooled to estimate the association between RDW and clinicopathological parameters of patients with hematologic malignances. RESULTS: Seven trials with 1031 patients suffering from hematological malignancies were included in the meta-analysis, and the results indicated that increased pretreatment RDW predicted poor overall survival (HR = 2.35, 95% CI 1.70–3.24), poor progress-free survival (HR = 2.44, 95% CI 1.70–3.49) and poor event-free survival (EFS) (HR = 3.15, 95% CI 1.59–6.25). Furthermore, the similar results were observed in subgroup analysis stratified by cancer type, such as multiple myeloma, and diffuse large B cell lymphoma, etc. CONCLUSIONS: As for hematologic malignances, patients with higher RDW are more likely to have poorer prognosis than those with lower RDW. BioMed Central 2018-04-23 /pmc/articles/PMC5914059/ /pubmed/29713244 http://dx.doi.org/10.1186/s12935-018-0558-3 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Primary Research
Ai, Lisha
Mu, Shidai
Hu, Yu
Prognostic role of RDW in hematological malignancies: a systematic review and meta-analysis
title Prognostic role of RDW in hematological malignancies: a systematic review and meta-analysis
title_full Prognostic role of RDW in hematological malignancies: a systematic review and meta-analysis
title_fullStr Prognostic role of RDW in hematological malignancies: a systematic review and meta-analysis
title_full_unstemmed Prognostic role of RDW in hematological malignancies: a systematic review and meta-analysis
title_short Prognostic role of RDW in hematological malignancies: a systematic review and meta-analysis
title_sort prognostic role of rdw in hematological malignancies: a systematic review and meta-analysis
topic Primary Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914059/
https://www.ncbi.nlm.nih.gov/pubmed/29713244
http://dx.doi.org/10.1186/s12935-018-0558-3
work_keys_str_mv AT ailisha prognosticroleofrdwinhematologicalmalignanciesasystematicreviewandmetaanalysis
AT mushidai prognosticroleofrdwinhematologicalmalignanciesasystematicreviewandmetaanalysis
AT huyu prognosticroleofrdwinhematologicalmalignanciesasystematicreviewandmetaanalysis